Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties

References

• Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother 2010;11:481–8
   PubMed Web of Science ®Google Scholar
• Raymond EG, Shannon C, Weaver MA, Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. Contraception 2013;87:26–37
   PubMed Web of Science ®Google Scholar
• Schaff EA. Mifepristone: ten years later. Contraception 2010;81:1–7
   PubMedGoogle Scholar
• Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 2011;31:436–40
   PubMed Web of Science ®Google Scholar
• Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing’s syndrome. Curr Opin Endocrinol Diabetes Obes 2012;19:295–9
   PubMed Web of Science ®Google Scholar
• Anibal F. The combination of mifepristone and misoprostol for the termination of pregnancy. Int J Gynaecol Obstet 2011;115:1–4
   PubMedGoogle Scholar
• Kovacs L, Sas M, Resch BA, et al. Termination of very early pregnancy by RU 486 – an antiprogestational compound. Contraception 1984;29:399–410
   PubMed Web of Science ®Google Scholar
• Marions L. Mifepristone dose in the regimen with misoprostol for medical abortion. Contraception 2006;74:21–5
   PubMedGoogle Scholar
• Kapp N, Borgatta L, Ellis SC, Stubblefield P. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion. Contraception 2006;73:525–7
   PubMed Web of Science ®Google Scholar
• Liao AH, Han XJ, Wu SY, et al. Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. Eur J Obstet Gynecol Reprod Biol 2004;116:211–16
   PubMedGoogle Scholar
• Li YT, Hsieh JC, Hou GQ, et al. Simultaneous use of mifepristone and misoprostol for early pregnancy termination. Taiwan J Obstet Gynecol 2011;50:11–14
   PubMed Web of Science ®Google Scholar
• Dahiya K, Mann S, Nanda S. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Arch Gynecol Obstet 2011;284:59–63
   PubMed Web of Science ®Google Scholar
• Mentula M, Suhonen S, Heikinheimo O. One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy – a randomized trial. Hum Reprod 2011;26:2690–7
   PubMedGoogle Scholar
• Chen QJ, Hou SP, Meads C, et al. Mifepristone in combination with prostaglandins for termination of 10-16 weeks’ gestation: a systematic review. Eur J Obstet Gynecol Reprod Biol 2011;159:247–54
   PubMedGoogle Scholar
• Gemzell-Danielsson K, Lalitkumar S. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management. Reprod Health Matters 2008;16:162–72
   PubMed Web of Science ®Google Scholar
• Hou SP, Fang AH, Chen QF, et al. Termination of second-trimester pregnancy by mifepristone combined with misoprostol versus intra-amnioticinjection of ethacridine lactate (Rivanol®): a systematic review of Chinese trials. Contraception 2011;84:214–23
   PubMed Web of Science ®Google Scholar
• Lalitkumar PG, Berger C, Gemzell-Danielsson K. Emergency contraception. Best Pract Res Clin Endocrinol Metab 2013;27:91–101
   PubMed Web of Science ®Google Scholar
• Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012;8:CD001324
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013;29 Suppl 1:1–14
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Berger C, P G L L. Emergency contraception – mechanisms of action. Contraception 2013;87:300–8
   PubMed Web of Science ®Google Scholar
• Taneepanichskul S. Emergency contraception with mifepristone 10 mg in Thai women. J Med Assoc Thai 2009;92:999–1002
   PubMedGoogle Scholar
• Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010;82:442–52
   PubMed Web of Science ®Google Scholar
• Agarwal M, Das V, Agarwal A, et al. Evaluation of mifepristone as a once a month contraceptive pill. Am J Obstet Gynecol 2009;200:e27–9
   PubMed Web of Science ®Google Scholar
• Meng CX, Andersson KL, Bentin-Ley U, et al. Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model. Fertil Steril 2009;91:256–64
   PubMed Web of Science ®Google Scholar
• Lal S, Kriplani A, Kulshrestha V, et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet 2010;109:128–30
   PubMed Web of Science ®Google Scholar
• Cleland K, Raymond E, Trussell J, et al. Ectopic pregnancy and emergency contraceptive pills: a systematic review. Obstetrics and Gynecology 2010;115:1263–6
   PubMed Web of Science ®Google Scholar
• Richardson AR, Maltz FN. Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception. Clin Ther 2012;34:24–36
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang W, Zhuang Y, et al. Effects of low-dose mifepristone administration in two different 14-day regimens on the menstrual cycle andendometrial development: a randomized controlled trial. Contraception 2011;84:64–70
   PubMed Web of Science ®Google Scholar
• Pei K, Xiao B, Jing X, et al. Weekly contraception with mifepristone. Contraception 2007;75:40–4
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:1175–89
   PubMed Web of Science ®Google Scholar
• Tristan M, Orozco LJ, Steed A, et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev 2012;8:CD007687
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux A, Bouchard P. The immninent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol 2012;358:232–43
   PubMed Web of Science ®Google Scholar
• Morgan FH, Laufgraben MJ. Mifepristone for management of Cushing’s syndrome. Pharmacotherapy 2013;33:319–29
   PubMed Web of Science ®Google Scholar
• Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454–62
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Jurik J, Schatzberg LD, et al. Slowing the progression of cognitive decline in Alzheimer’s disease using mifepristone. J Mol Neurosci 2002;19:201–6
   PubMedGoogle Scholar
• Revsin Y, Rekers NV, Louwe MC, et al. Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Neuropsychopharmacology 2009;34:747–58
   PubMed Web of Science ®Google Scholar
• Wulsin AC, Herman JP, Solomon MB. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010;35:1100–12
   PubMed Web of Science ®Google Scholar
• Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring) 2010;18:2295–300
   PubMed Web of Science ®Google Scholar
• Gross C, Blasey CM, Roe RL, et al. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 2009;26:959–69
   PubMed Web of Science ®Google Scholar